gefitinib has been researched along with leucine in 6 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (leucine) | Trials (leucine) | Recent Studies (post-2010) (leucine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 28,515 | 744 | 4,178 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H | 1 |
| Asahina, H; Dosaka-Akita, H; Kinoshita, I; Nishimura, M; Yamazaki, K; Yokouchi, H | 1 |
| Fukui, T; Furuta, K; Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yoshida, T | 1 |
| Imai, H; Ishizuka, T; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Nakajima, T; Oriuchi, N; Promchan, K; Shimizu, K; Sunaga, N; Tominaga, H; Yamamoto, N; Yanagitani, N | 1 |
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Liang, L; Wang, X; Yin, W | 1 |
1 trial(s) available for gefitinib and leucine
| Article | Year |
|---|---|
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Glutamic Acid; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Quinazolines; Treatment Outcome | 2006 |
5 other study(ies) available for gefitinib and leucine
| Article | Year |
|---|---|
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
Topics: Adenocarcinoma; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Isoleucine; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Serine; Valine | 2006 |
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids, Cyclic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Fusion Regulatory Protein-1; Gefitinib; Humans; Immunohistochemistry; Large Neutral Amino Acid-Transporter 1; Leucine; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases | 2010 |
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Co-Repressor Proteins; CTLA-4 Antigen; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glutamates; Humans; Leucine; Lung Neoplasms; Proline; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Transcription Factors | 2022 |